Although the novel tau aggregation inhibitor hydromethylthionine mesylate did not reach its coprimary endpoints, investigators insist there s more to the story ― especially with the control agent used.
AXS-05 statistically significantly delayed time to relapse of Alzheimer’s disease agitation versus placebo AXS-05 statistically significantly prevented relapse of Alzheimer’s disease. | November 28, 2022